|
|
|
NCRRs Division for Clinical Research Resources (DCRR) participates, along with other
NIH components, in two Federal grant programs that provide funding to small businesses.
The Small Business Innovation Research (SBIR) Program and the Small Business Technology
Transfer (STTR) Program both seek to increase the participation of small businesses
in Federally supported research and development (R&D) and to increase private
sector commercialization of technology developed through Federally supported R&D.
However, there are significant differences between the two programs. For detailed
program information, refer to the NIH Small Business Opportunities Web site.
Typically, the DCRR requests applications for grants, but it may solicit contract proposals.
DCRR is especially interested in the application of clinical technology, instruments,
devices and related methodologies that may have broad application to clinical
research, especially as it pertains to enhancing the ability to do clinical research.
- (R43-R44) Small Business Innovation Research (SBIR) grants support domestic
small business concerns to engage in research/research and development that has
the potential for commercialization. Phase I, which uses the R43 funding mechanism,
is normally for six months for an amount up to $100,000. Phase II, which uses
the R44 funding mechanism, is for two years and for up to $750,000. Receipt deadlines
for applications are April 1, August 1, and December 1 of each year. Refer
to the Clinical Research Guidelines for appropriate examples of clinical areas
of interest to DCRR.
- (R41-R42) Small Business Technology Transfer (STTR) grants support innovative
research in the United States that results in commercial products or services
that benefit the public. An STTR grant requires research partners at universities
and other non-profit research institutions to have a formal collaborative relationship
with the small business concern. At least 40 percent of the STTR research project
is to be conducted by the small business concern and at least 30 percent of the
work is to be conducted by the single, "partnering" research institution.
Phase I, which uses the R41 funding mechanism, is for one year for an amount up
to $100,000. Normally Phase II, which uses the R42 mechanism, is for two years
and for up to $500,000. This total includes direct costs, indirect costs, and
fixed fees. If justified, applicants may propose longer periods of time and greater
amounts of funds. Receipt deadlines for applications are April 1, August 1, and
December 1 of each year. Refer to the Clinical Research Guidelines for appropriate
examples of clinical areas of interest to DCRR.
|
|
| |
For further information, contact:
Director, Division for Clinical Research Resources
National Center for Research Resources
National Institutes of Health
One Democracy Plaza, Room 906
6701 Democracy Boulevard, MSC 4874
Bethesda, Maryland 20892-4874
Telephone: 301-435-0790
FAX: 301-480-3661
e-mail: CRADIR@ncrr.nih.gov
|
|